Latest Breaking News On - Chronic lymphocytic leukemia research programs - Page 1 : comparemela.com

Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCL

Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCL
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Gloria leslieJohn theurer cancer centerChronic lymphocytic leukemia research programsHackensack meridian school of medicineIndolent lymphomaHackensack meridian school

Pirtobrutinib Approval Adds Effective Third-Line Option to Previously Treated CLL/SLL Armamentarium

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for this population alongside the unmet needs it may address, highlights the efficacy and notable toxicities seen with the agent in the BRUIN study, and expands on the continued investigation of pirtobrutinib vs other standard-of-care regimens in various CLL subtypes.

United statesNew jerseyEli lillyGloria leslieHackensack meridian school of medicineNational comprehensive cancer networkHackensack meridian healthIndolent lymphomaChronic lymphocytic leukemia research programsJohn theurer cancer centerHackensack meridian schoolHackensack meridianCart cell therapyJohn theurer cancer center of hackensack meridian healthHackensack meridian school of medicineThird line

Dr Leslie on the Significance of the FDA Approval of Pirtobrutinib in Pretreated CLL and SLL

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Gloria leslieChronic lymphocytic leukemia research programsHackensack meridian school of medicineJohn theurer cancer centerIndolent lymphomaHackensack meridian school

Dr Leslie on the Clinical Benefit of Axi-Cel in Elderly Patients With R/R LBCL

Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma.

Gloria leslieChronic lymphocytic leukemia research programsHackensack meridian school of medicineJohn theurer cancer centerIndolent lymphomaHackensack meridian schoolJohn theurer cancer centerAxi celElderly patientsZuma 7

Dr Leslie on Outpatient CAR T-Cell Therapy Programs for Hematologic Malignancies

Lori A. Leslie, MD, discusses the benefits of implementing CAR T-cell therapy programs for patients with hematologic malignancies and highlights the successes with administering CAR T-cell therapy that JTCC has experienced.

Gloria leslieChronic lymphocytic leukemia research programsLymphoma divisionHackensack meridian school of medicineJohn theurer cancer centerIndolent lymphomaHackensack meridian schoolJohn theurer cancer centerImplementing cart cell therapy programsPatients with hematologic malignancies